Interim report, May-October 2020/21

News provided by

Elekta

26 Nov, 2020, 06:51 GMT

Stable performance during Covid

STOCKHOLM, Nov. 26, 2020 /PRNewswire/ -- In Elekta's second quarter, we managed to perform better than the overall radiotherapy market both in terms of orders and revenue despite continuous challenging circumstances. We also improved margins and stabilized cash flow. The launch of our new Harmony linac and regulatory clearances enhanced our product portfolio and strengthened our ability to deliver on our strategy of Precision Radiation Medicine.

Gustaf Salford
President and CEO

Second quarter           

  • Covid-19 continued to have a negative impact on Elekta's growth in the quarter            
  • Gross order intake amounted to SEK 3,627 M (4,036), corresponding to a 2 percent decrease in constant currency           
  • Net sales were SEK 3,534 M (3,709), corresponding to a 3 percent growth in constant currency            
  • Gross margin amounted to 40.9 (41.0) percent           
  • EBITA increased by 39 percent to SEK 752 M (539), corresponding to an EBITA margin of 21.3 percent (14.5)            
  • Earnings per share was SEK 0.98 (0.58) before/after dilution           
  • Cash flow after continuous investments improved by SEK 128 M to SEK 362 M (234)           
  • Launch of a new linac solution, Harmony

First six months           

  • Gross order intake amounted to SEK 8,078 M (8,426), corresponding to a 1 percent growth in constant currency            
  • Net sales were SEK 6,515 M (6,937), corresponding to a 1 percent decrease in constant currency           
  • Gross margin amounted to 43.2 (41.7) percent           
  • EBITA amounted to SEK 1,303 M (987), corresponding to an EBITA margin of 20.0 percent (14.2)           
  • Earnings per share was SEK 1.55 (0.96) before/after dilution           
  • Cash flow after continuous investments improved by SEK 939 M to SEK 389 M (-550)

Significant events after the quarter           

  • The Board of Director has appointed Gustaf Salford as Elekta's President and CEO with immediate effect.            
  • Introduction of Elekta Studio with the ImagingRing providing a complete image-guided brachytherapy workflow to a single room.

1 After continuous investments.
2 Before / after dilution.
3 Based on constant currency.

For further information, please contact:
Cecilia Ketels, Head of Investor Relations
Tel: +46 76 611 76 25, e-mail: cecilia.ketels@elekta.com
Time zone: CET: Central European Time

Johan Adebäck, Acting CFO, Elekta AB (publ)
Tel: +46 70 873 33 21, e-mail: johan.adeback@elekta.com
Time zone: CET: Central European Time

This is information that Elekta AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 07:30 CET on November 26, 2020. (REGMAR) 

About Elekta

For almost five decades, Elekta has been a leader in precision radiation medicine. Our more than 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to - and benefits from - more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com or follow @Elekta on Twitter.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/elekta/r/interim-report--may-october-2020-21,c3243789

The following files are available for download: